Studies of treatment of non-traumatic intracranial hemorrhage in newborn infants

1)对65例非外伤性颅内出血新生儿进行凝血功能检查。根据凝血功能检查结果，估计65例新生儿中有31例患有DIC和/或新生儿原发性出血性疾病。凝血功能异常组死亡率明显高于无凝血功能异常组。2）进一步研究加贝酯（FOY）和抗凝血酶Ⅲ浓缩液对新生儿DIC的影响。FOY在改善DIC临床表现方面上级肝素，尽管单独使用FOY治疗的患者组与其他治疗组之间在止血方面的实验室结果变化方面没有差异。结果表明，FOY治疗新生儿DIC的疗效优于肝素治疗。此外，FOY和抗凝血酶III浓缩物的联合治疗对新生儿DIC有效，其中单独给予FOY无效。3）我们给予6小时内的早产儿凝血因子XIII浓缩物，以检查其在降低严重颅内出血发生率方面的有效性。24名对照组婴儿中有7名（29%）持续脑室内出血，24名接受治疗的婴儿中有3名（13%）持续脑室内出血。治疗组和对照组中脑室内出血高危婴儿的严重脑室内出血发生率分别为20%和83%。凝血因子XIII浓缩物似乎对预防早产儿脑室内出血具有有益作用。

1) Coagulation studies were carried out in 65 newborn infants with non-traumatic intracranial hemorrhage. Based on the findings of coagulation status, it was estimated that 31 out of 65 neonates were suffered from DIC and/or primary hemorrhagic disease of the newborn. Mortality of the cases with coagualtion abnormalities was significantly higher than that of cases without coagulation abnormalities.2) Next study was carried out in order to clarify the effects of gabexate mesilate(FOY) and antithrombin III concentrates on DIC of newborn infants. FOY was superior to heparin in improvement of clinical findings of DIC, although no difference was seen in changes of loboratory findings on hemostasis between the patient group treated with FOY alone and the other treatment groups. Those results indicated that the administration of FOY was more effective than haparin therapy for the DIC of newborn infants. Furthermore, a combination therapy of FOY and antithrombin III concentrates is effective for the DIC in newborn infants in whom administration of FOY alone was not effective.3) We administered factor XIII concentrate to premature infants within 6 hours of age to examine its effectiveness in reducing the incidence of severe intracranial hemorrhage. Seven(29%) out of 24 control infants sustained intraventricular hemorrhage, and 3(13%) of 24 infants receiving the treatment did. Incidence of severe intraventricular hemorrhage in treated and control infants with high risk for intraventricular hemorrhage was 20% and 83% respectively. Factor XIII concentrate appears to have a beneficial effects on the prevention of intraventricular hemorrhage in premature infants.